AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of “Moderate Buy” by Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $37.6667.

Several equities research analysts have recently commented on the stock. Jefferies Financial Group lifted their price objective on shares of AxoGen from $29.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Canaccord Genuity Group lifted their price target on AxoGen from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Wall Street Zen lowered AxoGen from a “strong-buy” rating to a “buy” rating in a report on Saturday. HC Wainwright raised their price objective on AxoGen from $26.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Mizuho assumed coverage on AxoGen in a research report on Monday, December 1st. They issued an “outperform” rating and a $40.00 target price on the stock.

Insider Buying and Selling at AxoGen

In other news, Director Amy Mcbride Wendell sold 43,684 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total value of $1,280,378.04. Following the sale, the director directly owned 93,826 shares of the company’s stock, valued at $2,750,040.06. This represents a 31.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathy Johnson Weiler sold 46,653 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $29.55, for a total transaction of $1,378,596.15. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 301,680 shares of company stock worth $9,174,052. Corporate insiders own 2.78% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. First Light Asset Management LLC grew its position in shares of AxoGen by 28.2% during the 3rd quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider’s stock valued at $103,574,000 after acquiring an additional 1,276,487 shares during the period. Vanguard Group Inc. boosted its position in AxoGen by 7.1% during the fourth quarter. Vanguard Group Inc. now owns 2,869,955 shares of the medical equipment provider’s stock worth $93,934,000 after purchasing an additional 190,557 shares in the last quarter. Morgan Stanley grew its holdings in AxoGen by 6.5% in the fourth quarter. Morgan Stanley now owns 2,586,870 shares of the medical equipment provider’s stock valued at $84,668,000 after purchasing an additional 157,029 shares during the period. ArrowMark Colorado Holdings LLC grew its holdings in AxoGen by 20.4% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,958,406 shares of the medical equipment provider’s stock valued at $34,938,000 after purchasing an additional 332,498 shares during the period. Finally, Balyasny Asset Management L.P. increased its position in shares of AxoGen by 183.9% in the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after buying an additional 1,250,968 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Trading Down 1.7%

Shares of NASDAQ:AXGN opened at $31.20 on Monday. The business’s 50-day moving average is $33.08 and its 200 day moving average is $25.22. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.11 and a quick ratio of 3.31. AxoGen has a 1 year low of $9.22 and a 1 year high of $36.00. The firm has a market capitalization of $1.62 billion, a P/E ratio of -91.32 and a beta of 1.00.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, February 24th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%.The business had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $59.90 million. On average, research analysts predict that AxoGen will post -0.29 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.